论文部分内容阅读
有关鼻咽癌雌孕激素受体及癌基因的研究国内报道甚少。我们用免疫组化Ｓ－Ｐ法检测我院９８例经病理证实的鼻咽癌８项指标（ＥＲ、ＰＲ、Ｐ５３、Ｐ２１、ＰＣＮＡ、ＮＭ２３、ＥＭＡ、ＣＥＡ）。结果表明，鼻咽癌为雌孕激素受体高表达类肿瘤，阳性率为４８％、６１．２％，其受体水平可影响预后，故能结合内分泌治疗。受体水平还能反映临床分期变化，以使用于判断预后。Ｐ５３、Ｐ２１、ＰＣＮＡ、ＮＭ２３、ＥＭＡ、ＣＥＡ同时检测对判断复发病人有所帮助。在鼻咽癌中除Ｐ５３阳性率较低（２３．８％）外，其余５项均在５０～７８％之间。ＰＣＮＡ、ＮＭ２３与鼻咽癌Ｎ分期有关，但阳性表达相反。而ＥＭＡ、ＣＥＡ阳性表达与Ｔ分期有关，为协同表达。综合这几个指标对鼻咽癌临床分期判断、疗效观察、提示预后均有帮助，可应用于临床。
There are few reports on the research about estrogen and progesterone receptors and oncogenes in nasopharyngeal carcinoma. We used immunohistochemical S-P method in 98 cases of our hospital pathologically confirmed eight indicators of nasopharyngeal carcinoma (ER, PR, P53, P21, PCNA, NM23, EMA, CEA). The results showed that nasopharyngeal carcinoma is a high expression of estrogen and progesterone receptor tumors, the positive rate was 48%, 61.2%, its receptor levels can affect the prognosis, it can be combined with endocrine therapy. Receptor levels can also reflect clinical staging changes to be used to determine prognosis. P53, P21, PCNA, NM23, EMA, CEA simultaneous detection of patients to judge the recurrence of help. In addition to the low positive rate of P53 in nasopharyngeal carcinoma (23.8%), the remaining 5 are between 50 to 78%. PCNA, NM23 and nasopharyngeal N staging, but the positive expression of the opposite. The EMA, CEA positive expression and T staging related to synergistic expression. The combination of these indicators on the clinical stage of nasopharyngeal cancer judgment, the efficacy of observation, suggesting that the prognosis are helpful and can be applied to clinical.